Lasofoxifene Emerging Drug Insight

“Lasofoxifene Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Lasofoxifene for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Lasofoxifene for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the Lasofoxifene for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Lasofoxifene market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Drug Summary

Lasofoxifene is being investigated as a potent, bioavailable selective estrogen receptor modulator (SERM– also known as an estrogen agonist/antagonist) with a differentiated safety profile that could prove useful in the treatment of postmenopausal women and premenopausal women with ovarian suppression and locally advanced or metastatic ER+ breast cancer.

Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. The drugs’ novel activity in ESR1 mutations was discovered at Duke University, and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, if approved, could play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.

Lasofoxifene has demonstrated preclinical antitumor activity in ESR1-mutant models and is currently being investigated in different clinical trials. The Phase II ELAINE trial (NCT03781063) explores lasofoxifene versus fulvestrant in female patients with advanced luminal BC who have ESR1 mutations. Moreover, the Phase II ELAINE-2 trial (NCT04432454) is currently evaluating the combination of lasofoxifene plus abemaciclib in the same setting.

 

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Lasofoxifene description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on Lasofoxifene regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Lasofoxifene research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around Lasofoxifene.
• The report contains forecasted sales of Lasofoxifene for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the SWOT analysis with analyst views for Lasofoxifene in ER+ve HER2-ve Breast Cancer.

 

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Lasofoxifene Analytical Perspective by DelveInsight

 

• In-depth Lasofoxifene Market Assessment

This report provides a detailed market assessment of Lasofoxifene in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2025 to 2032.

 

• Lasofoxifene Clinical Assessment

The report provides the clinical trials information of Lasofoxifene in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

 

Report Highlights 

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lasofoxifene dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to Lasofoxifene and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lasofoxifene in ER+ve HER2-ve Breast Cancer.
• Our in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lasofoxifene in ER+ve HER2-ve Breast Cancer.  

 

Key Questions

• What is the product type, route of administration and mechanism of action of Lasofoxifene?
• What is the clinical trial status of the study related to Lasofoxifene in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lasofoxifene development?
• What are the key designations that have been granted to Lasofoxifene for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of Lasofoxifene for ER+ve HER2-ve Breast Cancer?
• What are the forecasted sales of Lasofoxifene in the United States? 
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to Lasofoxifene for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?